Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated (VRTX)
Compare

Vertex Pharmaceuticals Incorporated (VRTX) Debt to Equity Ratio: 0.21

popular:market cap|pe ratio|revenue|price history|total return

Is Vertex Pharmaceuticals Incorporated’s debt to equity ratio high or low?

Vertex Pharmaceuticals Incorporated's debt to equity ratio of 0.21 is 97% above its 5-year average of 0.11, near the high end of its 5-year range (0.05–0.21).

The debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 0.21 as of Wednesday, June 10, 2026. It is above its 12-month average by 31.25% (0.16).

Current Ratio|Quick Ratio|ROE|All Metrics

VRTX Debt to Equity Ratio Chart

VRTX Debt to Equity Ratio
0.21+90.91% 1Y
Zoom

VRTX Average Debt to Equity Ratio Chart

VRTX Current vs Average Debt to Equity Ratio Chart

VRTX Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.21

DEBT TO EQUITY RATIO AVG TTM

0.16

DEBT TO EQUITY RATIO AVG 3Y

0.11

DEBT TO EQUITY RATIO AVG 5Y

0.11

DEBT TO EQUITY RATIO AVG 10Y

0.25

DEBT TO EQUITY RATIO AVG 15Y

0.39

DEBT TO EQUITY RATIO AVG 20Y

0.41

CURRENT VS TTM AVG

+31.25%

CURRENT VS 3Y AVG

+95.35%

CURRENT VS 5Y AVG

+96.87%

CURRENT VS 10Y AVG

-17.20%

CURRENT VS 15Y AVG

-46.50%

CURRENT VS 20Y AVG

-49.37%

VRTX Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Vertex Pharmaceuticals Incorporated (VRTX)—0.210.160.110.11
Bristol-Myers Squibb Company (BMY)$114.14B2.552.842.101.84
Medtronic plc (MDT)$103.04B0.000.290.390.42
CVS Health Corporation (CVS)$125.16B1.241.171.091.10
Danaher Corporation (DHR)$130.25B0.350.350.370.43
Elevance Health Inc. (ELV)$87.43B0.760.780.740.71
Cigna Corporation (CI)$78.25B0.750.770.730.72
Pfizer Inc. (PFE)$146.36B0.780.770.680.63
Intuitive Surgical, Inc. (ISRG)$146.44B0.020.010.010.01
Gilead Sciences, Inc. (GILD)$151.21B1.091.231.191.29

Financial Health

Debt/Equity

0.21

Current Ratio

2.90

Vertex Pharmaceuticals Incorporated Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Vertex Pharmaceuticals Incorporated Debt to Equity Ratio FAQ

What is the debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The debt to equity ratio for VRTX stock is 0.21.
Is Vertex Pharmaceuticals Incorporated's debt to equity ratio high or low?
Vertex Pharmaceuticals Incorporated's debt to equity ratio of 0.21 is 97% above its 5-year average of 0.11, near the high end of its 5-year range (0.05–0.21).
What is the TTM average debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The TTM average debt to equity ratio for VRTX stock is 0.16.
What is the 3Y average debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 3Y average debt to equity ratio for VRTX stock is 0.11.
What is the 5Y average debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 5Y average debt to equity ratio for VRTX stock is 0.11.
What is the 10Y average debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 10Y average debt to equity ratio for VRTX stock is 0.25.
What is the 15Y average debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 15Y average debt to equity ratio for VRTX stock is 0.39.
What is the 20Y average debt to equity ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 20Y average debt to equity ratio for VRTX stock is 0.41.

Vertex Pharmaceuticals Incorporated Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2025-12-310.21
2024-12-310.11
2023-12-310.05
2022-12-310.06
2021-12-310.10
2020-12-310.11
2019-12-310.11
2018-12-310.13
2017-12-310.30
2016-12-310.73
2015-12-310.88
2014-12-310.77
2013-12-310.37
2012-12-310.70
2011-12-310.58
2010-12-311.07
2009-12-310.17
2008-12-311.20
2007-12-310.07
2006-12-310.24
2005-12-310.75
2004-12-319.45
2003-12-311.89
2002-12-310.87
2001-12-310.69
2000-12-310.70
1999-12-310.03
1998-12-310.04
1997-12-310.03
1996-12-310.06

Related Metrics

Current RatioQuick RatioROEAll Metrics

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA
6,100 employees
www.vrtx.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
View full financials